RU2016117052A - Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства - Google Patents
Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства Download PDFInfo
- Publication number
- RU2016117052A RU2016117052A RU2016117052A RU2016117052A RU2016117052A RU 2016117052 A RU2016117052 A RU 2016117052A RU 2016117052 A RU2016117052 A RU 2016117052A RU 2016117052 A RU2016117052 A RU 2016117052A RU 2016117052 A RU2016117052 A RU 2016117052A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- unsubstituted
- heteroaryl
- aryl
- absent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 26
- 238000001042 affinity chromatography Methods 0.000 title claims 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 claims 50
- 229910052717 sulfur Inorganic materials 0.000 claims 49
- 125000001072 heteroaryl group Chemical group 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims 40
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 33
- 229910052757 nitrogen Inorganic materials 0.000 claims 33
- 150000003839 salts Chemical class 0.000 claims 19
- 150000001409 amidines Chemical class 0.000 claims 12
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 12
- -1 2- (2- (2-amino-ethoxy) ethoxy) ethyl Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000003585 oxepinyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000003944 tolyl group Chemical group 0.000 claims 2
- 125000005023 xylyl group Chemical group 0.000 claims 2
- FRVQGCBWBSJTQC-UHFFFAOYSA-N CCc1nc(sc1C(=O)NCCOCCOCCN)N1CCC(CC1)C1CCN(CC1)C(=O)c1ccc(cc1)-c1nc2ccccc2[nH]1 Chemical compound CCc1nc(sc1C(=O)NCCOCCOCCN)N1CCC(CC1)C1CCN(CC1)C(=O)c1ccc(cc1)-c1nc2ccccc2[nH]1 FRVQGCBWBSJTQC-UHFFFAOYSA-N 0.000 claims 1
- ZFOFFCQSWVUJAX-UHFFFAOYSA-N NCCOCCOCCNC(=O)c1ccc2nc([nH]c2c1)-c1ccccc1 Chemical compound NCCOCCOCCNC(=O)c1ccc2nc([nH]c2c1)-c1ccccc1 ZFOFFCQSWVUJAX-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885146P | 2013-10-01 | 2013-10-01 | |
| US61/885,146 | 2013-10-01 | ||
| US201462025994P | 2014-07-17 | 2014-07-17 | |
| US62/025,994 | 2014-07-17 | ||
| PCT/IB2014/064998 WO2015049651A1 (en) | 2013-10-01 | 2014-10-01 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016117052A true RU2016117052A (ru) | 2017-11-10 |
| RU2016117052A3 RU2016117052A3 (enExample) | 2018-06-27 |
Family
ID=51743521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016117052A RU2016117052A (ru) | 2013-10-01 | 2014-10-01 | Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9809558B2 (enExample) |
| EP (1) | EP3052483B1 (enExample) |
| JP (1) | JP2016534984A (enExample) |
| KR (1) | KR20160060660A (enExample) |
| CN (1) | CN105593222B (enExample) |
| AU (1) | AU2014330781B2 (enExample) |
| BR (1) | BR112016007371A2 (enExample) |
| CA (1) | CA2925862A1 (enExample) |
| ES (1) | ES2721098T3 (enExample) |
| RU (1) | RU2016117052A (enExample) |
| SG (1) | SG11201601870VA (enExample) |
| WO (1) | WO2015049651A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10697982B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies |
| US10697983B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies |
| US20170066839A1 (en) | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
| JPWO2018181738A1 (ja) * | 2017-03-30 | 2020-02-13 | 日立化成株式会社 | 分離材 |
| US20220009959A1 (en) * | 2018-11-26 | 2022-01-13 | North Carolina State University | Peptide ligands for capture of host cell proteins |
| CA3123979A1 (en) | 2018-12-21 | 2020-06-25 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific protein |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
| EP4337202A4 (en) | 2021-06-18 | 2025-04-02 | Aligos Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| CA3240346A1 (en) | 2021-12-16 | 2023-06-22 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH187973A4 (de) * | 1973-02-09 | 1977-03-31 | Hoechst Ag | Verfahren zum optischen Aufhellen von Textilmaterialien |
| US4722896A (en) | 1981-01-26 | 1988-02-02 | The Beth Israel Hospital Association | Method for affinity purification of hybridoma antibodies |
| US5849874A (en) | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| JP2825755B2 (ja) * | 1993-04-07 | 1998-11-18 | 大塚製薬株式会社 | ピペリジン誘導体を有効成分とする末梢血管拡張剤および新規ピペリジン誘導体 |
| CA2182731A1 (en) * | 1994-02-03 | 1995-08-10 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
| GB9914825D0 (en) * | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
| EP1162196A4 (en) | 1999-12-27 | 2003-04-16 | Japan Tobacco Inc | COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AU2003222185A1 (en) | 2002-04-01 | 2003-10-20 | Utah Ventures Ii, L.P. | Tissue-specific endothelial membrane proteins |
| AU2003258022A1 (en) * | 2002-08-02 | 2004-02-23 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| EP2298770A1 (en) | 2005-11-03 | 2011-03-23 | ChemBridge Corporation | Heterocyclic compounds as TrkA modulators |
| RU2554854C9 (ru) | 2009-07-31 | 2017-02-03 | Асцендис Фарма Ас | Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля |
| US8614238B2 (en) * | 2009-10-19 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| EP2601208B1 (en) * | 2010-08-03 | 2015-02-11 | Graffinity Pharmaceuticals GmbH | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY |
| WO2012020080A2 (en) | 2010-08-12 | 2012-02-16 | Graffinity Pharmaceuticals Gmbh | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II |
| US9480751B2 (en) | 2011-04-11 | 2016-11-01 | Yeda Research And Development Co. Ltd. | Albumin binding probes and drug conjugates thereof |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
-
2014
- 2014-10-01 SG SG11201601870VA patent/SG11201601870VA/en unknown
- 2014-10-01 JP JP2016519325A patent/JP2016534984A/ja active Pending
- 2014-10-01 KR KR1020167008267A patent/KR20160060660A/ko not_active Withdrawn
- 2014-10-01 RU RU2016117052A patent/RU2016117052A/ru not_active Application Discontinuation
- 2014-10-01 BR BR112016007371A patent/BR112016007371A2/pt not_active Application Discontinuation
- 2014-10-01 ES ES14786355T patent/ES2721098T3/es active Active
- 2014-10-01 CA CA2925862A patent/CA2925862A1/en not_active Abandoned
- 2014-10-01 US US15/026,725 patent/US9809558B2/en not_active Expired - Fee Related
- 2014-10-01 AU AU2014330781A patent/AU2014330781B2/en not_active Ceased
- 2014-10-01 CN CN201480054551.4A patent/CN105593222B/zh not_active Expired - Fee Related
- 2014-10-01 WO PCT/IB2014/064998 patent/WO2015049651A1/en not_active Ceased
- 2014-10-01 EP EP14786355.9A patent/EP3052483B1/en active Active
-
2017
- 2017-09-07 US US15/698,020 patent/US9938243B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014330781B2 (en) | 2017-05-04 |
| EP3052483B1 (en) | 2019-02-06 |
| KR20160060660A (ko) | 2016-05-30 |
| CA2925862A1 (en) | 2015-04-09 |
| ES2721098T3 (es) | 2019-07-26 |
| WO2015049651A1 (en) | 2015-04-09 |
| JP2016534984A (ja) | 2016-11-10 |
| US20170369448A1 (en) | 2017-12-28 |
| CN105593222A (zh) | 2016-05-18 |
| RU2016117052A3 (enExample) | 2018-06-27 |
| US9809558B2 (en) | 2017-11-07 |
| SG11201601870VA (en) | 2016-04-28 |
| AU2014330781A1 (en) | 2016-04-07 |
| US9938243B2 (en) | 2018-04-10 |
| BR112016007371A2 (pt) | 2017-08-01 |
| EP3052483A1 (en) | 2016-08-10 |
| US20160221962A1 (en) | 2016-08-04 |
| CN105593222B (zh) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534984A5 (enExample) | ||
| ES2535166T3 (es) | Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| JP2016053042A5 (enExample) | ||
| JP2009511490A5 (enExample) | ||
| AR073046A1 (es) | Espiro compuestos inhibidores de beta - secretasa | |
| JP2006524222A5 (enExample) | ||
| AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| ES2927660T3 (es) | Compuestos para el tratamiento del cáncer | |
| AR063946A1 (es) | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
| CO6251317A2 (es) | Procedimiento para sintetizar sal diclorhidrato de ((1s)-1-(((2s) sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil | |
| RU2019118460A (ru) | Новые соединения замещенного n-(3-фторпропил)пирролидина, способы их получения и их терапевтическое применение | |
| JP2012508223A5 (enExample) | ||
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| AR077505A1 (es) | Compuestos de piridina y sus usos | |
| AR076375A1 (es) | Piperazinil azetidinil amidas heteroaromaticas y aromaticas como inhibidores de lipasas de monoacilglicerol. | |
| JP2014506599A5 (enExample) | ||
| AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
| RU2009141982A (ru) | Пиримидиновые производные | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190606 |